Compound, pharmaceutical composition, use of a compound, and, methods for treating a disease or disorder associated with pathogenic agonism, reverse agonism or antagonism of the gabaa receptor, to locate gabaa receptors in a tissue sample, to inhibit binding of a benzodiazepine compound to a gabaa receptor and to alter the signal transduction activity of gabaa receptors, and packaged pharmaceutical composition

摘要

"COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, AND, METHODS FOR THE TREATMENT OF A DISEASE OR DISORDER ASSOCIATED WITH PATHOGENIC AGONISM, REVERSE AGONISM OR ANTAGONISM OF THE GABA ~ ~ ~ RECOMMENDER, TO LOCATE A RECOVERY OF GABA ~ ~ ~ IN A RECOVERY LOCATION. TISSUE SAMPLE, TO INHIBIT THE CONNECTION OF A BENZODIAZEPINE COMPOUND TO A GABA ~ A ~ RECEIVER AND TO CHANGE THE SIGNAL TRANSDUCTION ACTIVITY OF GABA ~ A ~, AND, PACKED PHARMACEUTICAL COMPOSITION ". The compounds of formula (I) or their pharmaceutically acceptable salts are disclosed where R ~ 1 ~, R ~ 2 ~ and W are defined herein. These compounds are highly selective agonists, antagonists or inverse antagonists for brain GABAa receptors or prominences of agonists, antagonists or inverse agonists for brain GABAa receptors and are therefore useful in the diagnosis and treatment of anxiety, depression, Down, sleep and seizure disorders, overdose with benzodiazepine medications and memory enhancement. Pharmaceutical compositions that include packaged pharmaceutical compositions are also provided. The compounds of the invention are also useful as probes for locating GABA-A ~ receptors in tissue samples.